Search Result

Results for "

cognitive deficit

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (7) Adrenergic Receptor (6) Amyloid-β (3) Apoptosis (2) Autophagy (2) Bcl-2 Family (1) Calcium Channel (1) Caspase (1) Cholinesterase (ChE) (1) Dopamine Receptor (2) Endogenous Metabolite (2) GPR139 (1) GSK-3 (1) HDAC (2) iGluR (5) Interleukin Related (1) Isotope-Labeled Compounds (2) LPL Receptor (1) mAChR (2) mGluR (1) mTOR (1) nAChR (10) NF-κB (1) NOD-like Receptor (NLR) (2) Phosphodiesterase (PDE) (4) Reactive Oxygen Species (1) Sigma Receptor (1) SOD (1) TNF Receptor (1) Toll-like Receptor (TLR) (1) α-synuclein (1) γ-secretase (2)
By Research Areas:	Cancer (4) Cardiovascular Disease (4) Endocrinology (5) Inflammation/Immunology (4) Metabolic Disease (2) Neurological Disease (52)

By Targets:

5-HT Receptor (7)

Adrenergic Receptor (6)

Amyloid-β (3)

Apoptosis (2)

Autophagy (2)

Bcl-2 Family (1)

Calcium Channel (1)

Caspase (1)

Cholinesterase (ChE) (1)

Dopamine Receptor (2)

Endogenous Metabolite (2)

GPR139 (1)

GSK-3 (1)

HDAC (2)

iGluR (5)

Interleukin Related (1)

Isotope-Labeled Compounds (2)

LPL Receptor (1)

mAChR (2)

mGluR (1)

mTOR (1)

nAChR (10)

NF-κB (1)

NOD-like Receptor (NLR) (2)

Phosphodiesterase (PDE) (4)

Reactive Oxygen Species (1)

Sigma Receptor (1)

SOD (1)

TNF Receptor (1)

Toll-like Receptor (TLR) (1)

α-synuclein (1)

γ-secretase (2)

By Research Areas:

Cancer (4)

Cardiovascular Disease (4)

Endocrinology (5)

Inflammation/Immunology (4)

Metabolic Disease (2)

Neurological Disease (52)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-D0873

HEPPS EPPS	Amyloid-β	Neurological Disease
HEPPS (EPPS) is a buffering agent with the useful pH range from 7.3 ~ 8.7. HEPPS reduces Aβ-aggregate-induced memory deficits and rescues cognitive deficits in mice. EPPS is orally active and penetrates the blood-brain barrier .

HY-149651

GPR139 agonist-2	GPR139	Neurological Disease
GPR139 agonist-2 (compound 20a) is a potent GPR139 agonist with an EC₅₀ of 24.7 nM. GPR139 agonist-2 rescues the social interaction deficits and alleviates cognitive deficits in murine schizophrenia models. GPR139 agonist-2 has the potential for antischizophrenia drug research .

HY-115383

Roflupram 1 Publications Verification	Phosphodiesterase (PDE)	Neurological Disease Inflammation/Immunology
Roflupram is a selective, orally active and brain-penetrant PDE4 inhibitor, with an IC₅₀ of 26.2 nM for core catalytic domains of human PDE4. Roflupram can reverse cognitive deficits and reduce the production of pro-inflammatory factors .

HY-116565

Usmarapride SUVN-D4010	5-HT Receptor	Neurological Disease
Usmarapride (SUVN-D4010) is a potent, selective, orally active and brain penetrant 5-HT₄ receptor partial agonist (EC₅₀=44 nM). Usmarapride (SUVN-D4010) can be used for the research of cognitive deficits associated with Alzheimer's disease .

HY-116565A

Usmarapride free base SUVN-D4010 free base	5-HT Receptor	Neurological Disease
Usmarapride (SUVN-D4010) free base is a potent, selective, orally active and brain penetrant 5-HT₄ receptor partial agonist (EC₅₀=44 nM). Usmarapride (SUVN-D4010) free base can be used for the research of cognitive deficits associated with Alzheimer's disease .

HY-59201A

A-582941 dihydrochloride	nAChR 5-HT Receptor	Neurological Disease
A-582941 dihydrochloride is a potent, selective and brain-penetrant partial agonist of α7 nAChR, with K_is of 10.8 and 16.7 nM in rat brain membranes and human frontal cortex, respectively. A-582941 dihydrochloride also binds to human 5-HT₃ receptor with a K_i of 150 nM. A-582941 has the potential for cognitive deficits associated with various neurodegenerative and psychiatric disorders research .

HY-N10408

Tripchlorolide	Apoptosis Autophagy	Neurological Disease Cancer
Tripchlorolide is a neuroprotective agent that can be found in Tripterygium wilfordii. Tripchlorolide prevents tumor growth by inducing apoptosis and autophagy. Tripchlorolide improves cognitive deficits in Alzheimer's disease .

HY-168264

MC1	NOD-like Receptor (NLR)	Neurological Disease
MC1 is a potent NLRP3 inhibitor with a K_D value of 19.3 nM. MC1 shows no cytotoxicity. MC1 ameliorates cognitive deficits without eliciting adverse effects and shows an absence of hepatotoxicity. MC1 has the potential for the research of Alzheimer's disease (AD) .

HY-155116

5-HT6 agonist 1	5-HT Receptor	Neurological Disease
5-HT6 agonist 1 (Compound 19) is a 5-HT6 agonist (K_i: 5 nM). 5-HT6 agonist 1 has antidepressant-like properties, and improves cognitive deficits. 5-HT6 agonist 1 also inhibits platelet aggregation. 5-HT6 agonist 1 has high metabolic stability .

HY-118575

DR-4004	5-HT Receptor	Neurological Disease
DR-4004 is a 5-HT₇ receptor antagonist that attenuates the decreased level of performance produced by mCPP and the performance levels after p-chloroamphetamine (PCA) lesion of the 5-HT system. DR-4004 also reverses amnesia induced by Scopolamine (HY-N0296) and Dizocilpine (HY-15084B). DR-4004 is promising for research of schizophrenia, cognitive deficits and atypical antipsychotic agents .

HY-P3355

p-fin4	iGluR	Neurological Disease
p-fin4 is a peptide inhibitor of STEP Phosphatase-GluA2 AMPA receptor interaction with a Ki of 0.4 μM. p-fin4 restores the memory deficits and displays anxiolytic and antidepressant effects in a scopolamine-treated rat model. p-fin4 is a promising lead compound for novel cognitive enhancers and/or behavioral modulators .

HY-P3354

p3Ysh-3	iGluR	Neurological Disease
p3Ysh-3 is a peptide inhibitor of STEP Phosphatase-GluA2 AMPA receptor interaction with a Ki of 1.09 μM. p3Ysh-3 restores the memory deficits and displays anxiolytic and antidepressant effects in a scopolamine-treated rat model. p3Ysh-3 is a promising lead compound for novel cognitive enhancers and/or behavioral modulators .

HY-17416A

Guanfacine	Adrenergic Receptor	Neurological Disease Endocrinology
Guanfacine is an orally active noradrenergic α2A agonist and has high selective for the α2A receptor subtype. Guanfacine has effects in producing hypotension and sedation. Guanfacine can be used for the research of a variety of prefrontal cortex (PFC) cognitive disorders, including tourette's syndrome and attention deficit hyperactivity disorder (ADHD) .

HY-17416

Guanfacine hydrochloride 2 Publications Verification	Adrenergic Receptor	Cardiovascular Disease Endocrinology
Guanfacine hydrochloride is an orally active noradrenergic α2A agonist and has high selective for the α2A receptor subtype. Guanfacine has effects in producing hypotension and sedation. Guanfacine can be used for the research of a variety of prefrontal cortex (PFC) cognitive disorders, including tourette's syndrome and attention deficit hyperactivity disorder (ADHD) .

HY-147720A

γ-Secretase modulator 11 hydrochloride	γ-secretase	Neurological Disease
γ-Secretase modulator 11 hydrochloride (compound 1o) is a potent and orally active γ-secretase modulator with an IC₅₀ of 0.029 µM. γ-Secretase modulator 11 hydrochloride induces a robust reduction in brain Aβ42 levels. γ-Secretase modulator 11 hydrochloride rescues cognitive deficits exhibited by AD model mice. γ-Secretase modulator 11 hydrochloride has the potential for the research of alzheimer's disease .

HY-17416R

Guanfacine hydrochloride (Standard)	Adrenergic Receptor	Cardiovascular Disease Endocrinology
Guanfacine (hydrochloride) (Standard) is the analytical standard of Guanfacine (hydrochloride). This product is intended for research and analytical applications. Guanfacine hydrochloride is an orally active noradrenergic α2A agonist and has high selective for the α2A receptor subtype. Guanfacine has effects in producing hypotension and sedation. Guanfacine can be used for the research of a variety of prefrontal cortex (PFC) cognitive disorders, including tourette's syndrome and attention deficit hyperactivity disorder (ADHD) .

HY-17416AS1

Guanfacine-15N3,13C2	Adrenergic Receptor Isotope-Labeled Compounds	Neurological Disease Endocrinology
Guanfacine- ¹⁵N₃, ¹³C₂ is ¹⁵N and ¹³C labeled Guanfacine (HY-17416A). Guanfacine is an orally active noradrenergic α2A agonist and has high selective for the α2A receptor subtype. Guanfacine has effects in producing hypotension and sedation. Guanfacine can be used for the research of a variety of prefrontal cortex (PFC) cognitive disorders, including tourette's syndrome and attention deficit hyperactivity disorder (ADHD) .

HY-11013

ZSET1446 ST-101	Calcium Channel nAChR	Neurological Disease Cancer
ZSET1446 is a novel cognitive enhancer that significantly improves learning deficits in various types of Alzheimer disease (AD) models.

HY-148325

α7 Nicotinic receptor agonist-1	nAChR	Neurological Disease
α7 Nicotinic receptor agonist-1 (Preparation 5) is an α7 nAChR agonist. α7 Nicotinic receptor agonist-1 can be used in studies of psychiatric disorders (such as schizophrenia, manic or hypomanic depression and anxiety disorders) and intellectual disorders (such as alzheimer's disease, learning deficits, cognitive deficits, attention deficits, memory loss, lewy body dementia and attention deficit hyperactivity disorder) .

HY-105435

FR121196	Others	Neurological Disease
FR121196 is a cognitive enhancer, and ameliorates Scopolamine (HY-N0296)-induced memory deficit. FR121196 is an antidementia compound .

HY-133712

Yonkenafil Tunodafil	Phosphodiesterase (PDE)	Neurological Disease
Yonkenafil (Tunodafil), a novel phosphodiesterase 5 (PDE5) inhibitor, is effective in reducing cerebral infarction, neurological deficits, edema, and neuronal damage in the infarcted area. Yonkenafil may improve cognitive function by modulating neurogenesis and has a potential therapeutic effect on Alzheimer's disease .

HY-125095

Yonkenafil hydrochloride Tunodafil hydrochloride	Phosphodiesterase (PDE)	Cardiovascular Disease Neurological Disease
Yonkenafil (Tunodafil) hydrochloride, a novel phosphodiesterase 5 (PDE5) inhibitor, is effective in reducing cerebral infarction, neurological deficits, edema, and neuronal damage in the infarcted area. Yonkenafil (Tunodafil) hydrochloride may improve cognitive function by modulating neurogenesis and has a potential therapeutic effect on Alzheimer's disease .

HY-17553

Coluracetam 3 Publications Verification MKC-231	iGluR	Neurological Disease
Coluracetam (MKC-231) is an orally taken choline uptake enhancer. Coluracetam can improve the reduced acetylcholine levels in the hippocampus of rats and mice, enhancing learning difficulties, memory deficits, and cognitive impairments. Coluracetam induces a lower degree of hepatic venous hyperglycemia .

HY-123661

MIPS1455	Others	Neurological Disease
MIPS1455 is a light-activated M1 muscarinic acetylcholine receptor ligand with irreversible binding activity to the allosteric site of the receptor. MIPS1455 is a drug target under investigation for the suppression of cognitive deficits and may become a valuable molecular tool for further investigation of allosteric interactions of the receptor .

HY-112781

Pesampator PF-04958242	iGluR	Neurological Disease
Pesampator (PF-04958242) is a potent and highly selective positive allosteric modulator of AMPA receptor (an AMPA potentiator) with an EC₅₀ of 310 nM and a K_i of 170 nM .

HY-157999

SDI-118	Others	Neurological Disease
SDI-118 is an orally active modulator for synaptic vesicle glycoprotein 2A (SV2A) with an IC₅₀ of 13 nM .

HY-116881

SCH 57790	mAChR	Neurological Disease
SCH 57790 is a selective antegonist for muscarinic M2 receptor, which increases acetylcholine release, and thus improves cognitive performance. SCH 57790 reverses Scopolamine (HY-N0296)-induced memory deficits in mice, without significant toxicity (100 mg/kg).

HY-118342

PQCA	mAChR	Neurological Disease
PQCA is a highly selective and potent muscarinic M1 receptor positive allosteric modulator. PQCA has an EC₅₀ value of 49 nM and 135 nM on rhesus and human M1 receptor, respectively. PQCA is inactive for other muscarinic receptors. PQCA has potential to reduce the cognitive deficits associated with Alzheimer's disease .

HY-W010041

Scyllo-Inositol	Amyloid-β Endogenous Metabolite	Neurological Disease
Scyllo-Inositol, an amyloid inhibitor, potentialy inhibits α-synuclein aggregation. Scyllo-Inositol stabilizes a non-fibrillar non-toxic form of amyloid-β peptide (Aβ42) in vitro, reverses cognitive deficits, and reduces synaptic toxicity and lowers amyloid plaques in an Alzheimer's disease mouse model .

HY-162339

BChE-IN-30	Cholinesterase (ChE)	Neurological Disease
BChE-IN-30 (compound (R)-37a) is a BChE inhibitor (IC₅₀: 5 nM) with anti-inflammatory activity and low toxicity. BChE-IN-30 can improve cognitive deficits induced by scopolamine and Aβ1-42 peptide and can be used in the study of late-stage AD .

HY-N11872

Suffruticosol A	Others	Neurological Disease
Suffruticosol A is a neuroprotective agent that restores scopolamine-induced cellular neurodegenerative damage. Suffruticosol A ameliorates hippocampal cholinergic deficits and partially enhances BDNF signaling. Suffruticosol A has neuromodulatory effects in a Scopolamine (HY-N0296)-induced model, restoring memory and cognitive performance in mice. Suffruticosol A can be isolated from seeds of P. lactiflora .

HY-14824A

Sofinicline benzenesulfonate ABT 894 benzenesulfonate	nAChR	Neurological Disease
Sofinicline benzenesulfonate (ABT 894 benzenesulfonate) is a novel nicotinic acetylcholine receptor agonist, specifically acting on the α4β2 subtype of nAChR (IC₅₀=0.1 nM). Sofinicline benzenesulfonate has the potential to improve cognitive function, including attention, memory and working memory. Sofinicline benzenesulfonate can be used in studies of attention deficit, hyperactivity disorder (ADHD) .

HY-129517

UBP714	iGluR	Neurological Disease
UBP714 exhibts agonistic activity for recombinant GluN1/GluN2 receptor by binding to the positive allosteric site (PAM) of NMDARs. UBP714 enhances NMDAR-mediated field excitatory postsynaptic potentials (f-EPSPs) in Xenopus oocytes .

HY-118956

Adrogolide hydrochloride ABT-431 hydrochloride; DAS-431 hydrochloride	Dopamine Receptor	Neurological Disease
Adrogolide hydrochloride (ABT-431 hydrochloride) is a chemically stable prodrug that can convert to the dopamine D1 receptor agonist A-86929. Adrogolide hydrochloride ameliorates the MPTP (HY-15608)-induced Parkinson's Disease in marmoset model, reduces the dyskinesias tendency. Adrogolide hydrochloride reverses Risperidone (HY-11018)-induced cognitive deficits in monkey .

HY-P1173

L803-mts Myristoylated L 803; GSK-3β Inhibitor XIII	GSK-3 Amyloid-β	Neurological Disease
L803-mts (Myristoylated L 803) is a selective and substrate-competitive GSK-3 peptide inhibitor (IC₅₀: 40 μM). L803-mts also reduces Aβ deposits and ameliorates cognitive deficits in 5XFAD mice. L803-mts shows antidepressive effect in the forced swimming test .

HY-155484

SOMCL-668	Sigma Receptor	Neurological Disease
SOMCL-668 is a selective and potent sigma-1 receptor allosteric modulator. ?SOMCL-668 shows positive modulation of improvement in social deficits and cognitive impairment induced by the selective sigma-1 agonist PRE084.?SOMCL-668 displays anti-seizure activities and can be used for psychotic illness research .

HY-107676

SIB-1553A	nAChR	Neurological Disease
SIB-1553A is an orally bioavailable nicotinic acetylcholine receptors (nAChRs) agonist, with selectivity for β4 subunit-containing nAChRs. SIB-1553A is also a selective neuronal nAChR ligand. SIB-1553A is a cognitive enhancer, and has therapeutic potential for the symptomatic treatment of Alzheimer’s disease and other cognitive disorders .

HY-B0731A

Perospirone SM-9018 free base	5-HT Receptor Dopamine Receptor	Neurological Disease
Perospirone (SM-9018 free base) is an orally active antagonist of 5-HT_2A receptor (K_i=0.6 nM) and dopamine D₂ receptor (K_i=1.4 nM), and also a partial agonist of 5-HT_1A receptor (K_i=2.9 nM). Perospirone is an atypical antipsychotic agent and has the potential for schizophrenic disease research .

HY-107676A

SIB-1553A free base	nAChR	Neurological Disease
SIB-1553A free base is an orally bioavailable nicotinic acetylcholine receptors (nAChRs) agonist, with selectivity for β4 subunit-containing nAChRs. SIB-1553A free base is also a selective neuronal nAChR ligand. SIB-1553A free base is a cognitive enhancer, and has therapeutic potential for the symptomatic treatment of Alzheimer’s disease and other cognitive disorders .

HY-17416AS

Guanfacine-13C,15N3	Adrenergic Receptor	Neurological Disease
Guanfacine- ¹³C, ¹⁵N₃ is the ¹³C and ¹⁵N labeled Guanfacine[1]. Guanfacine is an orally active noradrenergic α2A agonist and has high selective for the α2A receptor subtype. Guanfacine has effects in producing hypotension and sedation. Guanfacine can be used for the research of a variety of prefrontal cortex (PFC) cognitive disorders, including tourette's syndrome and attention deficit hyperactivity disorder (ADHD)[2][3][4].

HY-17416S2

Guanfacine-13C,d5 hydrochloride	Adrenergic Receptor Isotope-Labeled Compounds	Cardiovascular Disease Endocrinology
Guanfacine- ¹³C,d₅ hydrochloride is the deuterium and ¹³C labeled Guanfacine hydrochloride (HY-17416). Guanfacine hydrochloride is an orally active noradrenergic α2A agonist and has high selective for the α2A receptor subtype. Guanfacine has effects in producing hypotension and sedation. Guanfacine can be used for the research of a variety of prefrontal cortex (PFC) cognitive disorders, including tourette's syndrome and attention deficit hyperactivity disorder (ADHD) .

HY-133011

nAChR agonist 1	nAChR	Neurological Disease
nAChR agonist 1 is a potent, brain-permeable, and orally efficacious positive allosteric modulator of α7 nicotinic acetylcholine receptor (α7 nAChR). nAChR agonist 1 has the EC₅₀ of 0.32 µM in a Ca ²⁺ mobilization assay (PNU-282987-induced, FLIPR based) in human IMR-32 neuroblastoma cells that endogenously express α7 nAChR. nAChR agonist 1 can be develpoped for the treatment of Alzheimer’s disease .

HY-121249

Capeserod hydrochloride SL65.0155	5-HT Receptor	Neurological Disease
Capeserod hydrochloride (SL65.0155) is a 5-HT_4(e) receptor partial agonist (K_i=0.6 nM) with potent cognitive enhancing properties. Capeserod hydrochloride acts as a partial agonist in cells expressing 5-HT_4(b) and 5-HT_4(e) splice variants, stimulating cAMP production with IC₅₀ values ??of 244 and 29 nM, respectively. Capeserod hydrochloride is used in the study of memory impairment and dementia .

HY-162566

REM127	Others	Neurological Disease
REM127 is a small molecule compound capable of modulating calcium homeostasis in cells and possesses neuroprotective effects. REM127 can restore the calcium homeostasis imbalance in cellular models caused by pathological accumulation of tau protein. REM127 can efficiently cross the blood-brain barrier, and it has the potential to rescue synaptic and cognitive deficits in Alzheimer's disease animal models, as well as to slow down the progression of amyloid-beta and tau protein pathologies. REM127 can be used for research in neurodegenerative diseases .

HY-156331

VU6004909	mGluR	Neurological Disease
VU6004909 is a blood-brain barrier penetrated mGlu1 positive allosteric modulator (PAM), with the EC₅₀s of 25.7 nM and 31 nM for human mGlu1 and rat mGlu1, respectively. VU6004909 reduces dorsolateral striatal dopamine (DA) release in vivo and displays antipsychotic efficacy .

HY-123976

MPT0G211	HDAC	Neurological Disease Cancer
MPT0G211 is a potent, orally active and selective HDAC6 inhibitor (IC₅₀=0.291 nM). MPT0G211 displays >1000-fold selective for HDAC6 over other HDAC isoforms. MPT0G211 can penetrate the blood-brain barrier. MPT0G211 ameliorates tau phosphorylation and cognitive deficits in an Alzheimer’s disease model. MPT0G211 has anti-metastatic and neuroprotective effects. Anticancer activities .

HY-123976A

MPT0G211 mesylate	HDAC	Neurological Disease Cancer
MPT0G211 mesylate is a potent, orally active and selective HDAC6 inhibitor (IC₅₀=0.291 nM). MPT0G211 mesylate displays >1000-fold selective for HDAC6 over other HDAC isoforms. MPT0G211 mesylate can penetrate the blood-brain barrier. MPT0G211 mesylate ameliorates tau phosphorylation and cognitive deficits in an Alzheimer’s disease model. MPT0G211 mesylate has anti-metastatic and neuroprotective effects. Anticancer activities .

HY-105670

PHA-543613	nAChR	Neurological Disease
PHA-543613 is a potent, orally active, brain-penetrant and selective α7 nAChR agonist with a K_i of 8.8 nM. PHA-543613 displays selectivity for α7-nAChR over α3β4, α1β1γδ, α4β2 and 5-HT3 receptors . PHA-543613 can be used for the cognitive deficits of Alzheimer's disease and schizophrenia research .

HY-147720

γ-Secretase modulator 11	γ-secretase	Neurological Disease
5-{8-[(3,4'- difluoro [1,1'- biphenyl]-4-yl) methoxy] - 2-methylimidazo [1,2-a] pyridin-3-yl}-n-methylpyridin-2-formamide (1o) showed high potency in vitro and brain exposure, inducing brain a β 42 levels were significantly reduced and showed undetectable inhibition of cytochrome P450 enzymes. In addition, compound 1o showed excellent anti cognitive deficit effect in AD model mice.

HY-105670B

PHA-543613 dihydrochloride	nAChR	Neurological Disease
PHA-543613 dihydrochloride is a potent, orally active, brain-penetrant and selective α7 nAChR agonist with a K_i value of 8.8 nM. PHA-543613 dihydrochloride displays selectivity for α7-nAChR over α3β4, α1β1γδ, α4β2 and 5-HT3 receptors . PHA-543613 dihydrochloride can be used for the cognitive deficits of Alzheimer's disease and schizophrenia research .

Cat. No.	Product Name	Type

HY-D0873

HEPPS EPPS	Buffer Reagents
HEPPS (EPPS) is a buffering agent with the useful pH range from 7.3 ~ 8.7. HEPPS reduces Aβ-aggregate-induced memory deficits and rescues cognitive deficits in mice. EPPS is orally active and penetrates the blood-brain barrier .

Cat. No.	Product Name	Target	Research Area

HY-P3355

p-fin4	iGluR	Neurological Disease
p-fin4 is a peptide inhibitor of STEP Phosphatase-GluA2 AMPA receptor interaction with a Ki of 0.4 μM. p-fin4 restores the memory deficits and displays anxiolytic and antidepressant effects in a scopolamine-treated rat model. p-fin4 is a promising lead compound for novel cognitive enhancers and/or behavioral modulators .

HY-P3354

p3Ysh-3	iGluR	Neurological Disease
p3Ysh-3 is a peptide inhibitor of STEP Phosphatase-GluA2 AMPA receptor interaction with a Ki of 1.09 μM. p3Ysh-3 restores the memory deficits and displays anxiolytic and antidepressant effects in a scopolamine-treated rat model. p3Ysh-3 is a promising lead compound for novel cognitive enhancers and/or behavioral modulators .

HY-P1173

L803-mts Myristoylated L 803; GSK-3β Inhibitor XIII	GSK-3 Amyloid-β	Neurological Disease
L803-mts (Myristoylated L 803) is a selective and substrate-competitive GSK-3 peptide inhibitor (IC₅₀: 40 μM). L803-mts also reduces Aβ deposits and ameliorates cognitive deficits in 5XFAD mice. L803-mts shows antidepressive effect in the forced swimming test .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-W010041

Scyllo-Inositol	Structural Classification Natural Products Source classification Endogenous metabolite	Amyloid-β Endogenous Metabolite
Scyllo-Inositol, an amyloid inhibitor, potentialy inhibits α-synuclein aggregation. Scyllo-Inositol stabilizes a non-fibrillar non-toxic form of amyloid-β peptide (Aβ42) in vitro, reverses cognitive deficits, and reduces synaptic toxicity and lowers amyloid plaques in an Alzheimer's disease mouse model .

HY-W012722

4-Methyl-2-oxopentanoic acid 1 Publications Verification α-Ketoisocaproic acid	Structural Classification Human Gut Microbiota Metabolites Immune System Disorder Microorganisms Ketones, Aldehydes, Acids Source classification Disease markers Endogenous metabolite	Endogenous Metabolite Autophagy mTOR SOD
4-Methyl-2-oxopentanoic acid (α-Ketoisocaproic acid) is a metabolite of L-leucine and is involved in energy metabolism. 4-Methyl-2-oxopentanoic acid increases endoplasmic reticulum stress, promotes lipid accumulation in preadipocytes and insulin resistance by impairing mTOR and autophagy signaling pathways. 4-Methyl-2-oxopentanoic acid also causes oxidative damage, leading to cognitive deficits, inhibits α-ketoglutarate dehydrogenase activity, acts as an oxidative phosphorylation uncoupler and metabolic inhibitor. 4-Methyl-2-oxopentanoic acid acts as a nutrient signal and stimulates skeletal muscle protein synthesis. 4-Methyl-2-oxopentanoic acid can be used in the study of maple syrup urine disease .

HY-N11872

Suffruticosol A	Structural Classification Paeonia lactiflora Pall. Source classification Phenols Polyphenols Plants Paeoniaceae	Others
Suffruticosol A is a neuroprotective agent that restores scopolamine-induced cellular neurodegenerative damage. Suffruticosol A ameliorates hippocampal cholinergic deficits and partially enhances BDNF signaling. Suffruticosol A has neuromodulatory effects in a Scopolamine (HY-N0296)-induced model, restoring memory and cognitive performance in mice. Suffruticosol A can be isolated from seeds of P. lactiflora .

HY-130398

Aerophobin-2	Structural Classification Natural Products Marine natural products Source classification Sponge	α-synuclein
Aerophobin-2 is a bromine compound, which can be isolated from sponge Verongia aerophoba. Aerophobin-2 inhibits aggregation of α-synuclein (α-syn) and phosphorylated α-synuclein (pSyn), exhibits neuroprotective efficacy .

Cat. No.	Product Name	Chemical Structure

HY-17416AS1

Guanfacine-15N3,13C2

Guanfacine- ¹⁵N₃, ¹³C₂ is ¹⁵N and ¹³C labeled Guanfacine (HY-17416A). Guanfacine is an orally active noradrenergic α2A agonist and has high selective for the α2A receptor subtype. Guanfacine has effects in producing hypotension and sedation. Guanfacine can be used for the research of a variety of prefrontal cortex (PFC) cognitive disorders, including tourette's syndrome and attention deficit hyperactivity disorder (ADHD) .

HY-17416AS

Guanfacine-13C,15N3

Guanfacine- ¹³C, ¹⁵N₃ is the ¹³C and ¹⁵N labeled Guanfacine[1]. Guanfacine is an orally active noradrenergic α2A agonist and has high selective for the α2A receptor subtype. Guanfacine has effects in producing hypotension and sedation. Guanfacine can be used for the research of a variety of prefrontal cortex (PFC) cognitive disorders, including tourette's syndrome and attention deficit hyperactivity disorder (ADHD)[2][3][4].

HY-17416S2

Guanfacine-13C,d5 hydrochloride

Guanfacine- ¹³C,d₅ hydrochloride is the deuterium and ¹³C labeled Guanfacine hydrochloride (HY-17416). Guanfacine hydrochloride is an orally active noradrenergic α2A agonist and has high selective for the α2A receptor subtype. Guanfacine has effects in producing hypotension and sedation. Guanfacine can be used for the research of a variety of prefrontal cortex (PFC) cognitive disorders, including tourette's syndrome and attention deficit hyperactivity disorder (ADHD) .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks